- Home
- ARTV vs RNXT Comparison
ARTV vs RNXT Comparison
Compare ARTV & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTV
- RNXT
- Stock Information
- Founded
- ARTV 2019
- RNXT 2012
- Country
- ARTV United States
- RNXT United States
- Employees
- ARTV N/A
- RNXT N/A
- Industry
- ARTV
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- ARTV
- RNXT Health Care
- Exchange
- ARTV NYSE
- RNXT Nasdaq
- Market Cap
- ARTV 50.7M
- RNXT 44.6M
- IPO Year
- ARTV 2024
- RNXT 2021
- Fundamental
- Price
- ARTV $1.63
- RNXT $1.36
- Analyst Decision
- ARTV Strong Buy
- RNXT Strong Buy
- Analyst Count
- ARTV 8
- RNXT 2
- Target Price
- ARTV $18.14
- RNXT $7.25
- AVG Volume (30 Days)
- ARTV 155.1K
- RNXT 190.7K
- Earning Date
- ARTV 05-08-2025
- RNXT 08-12-2025
- Dividend Yield
- ARTV N/A
- RNXT N/A
- EPS Growth
- ARTV N/A
- RNXT N/A
- EPS
- ARTV N/A
- RNXT N/A
- Revenue
- ARTV N/A
- RNXT $240,000.00
- Revenue This Year
- ARTV N/A
- RNXT $3,186.05
- Revenue Next Year
- ARTV N/A
- RNXT $291.93
- P/E Ratio
- ARTV N/A
- RNXT N/A
- Revenue Growth
- ARTV N/A
- RNXT N/A
- 52 Week Low
- ARTV $1.55
- RNXT $0.75
- 52 Week High
- ARTV $17.31
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- ARTV N/A
- RNXT 58.97
- Support Level
- ARTV N/A
- RNXT $1.26
- Resistance Level
- ARTV N/A
- RNXT $1.40
- Average True Range (ATR)
- ARTV 0.00
- RNXT 0.05
- MACD
- ARTV 0.00
- RNXT -0.01
- Stochastic Oscillator
- ARTV 0.00
- RNXT 48.70
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.